London Stock Exchange · Healthcare
Invest in Renalytix stock from India
Indian and foreign residents can buy Renalytix (RENX) shares directly through Paasa.
By Paasa · Updated
Renalytix at a glance
- Price
- £0.06+£0.00 (4.13%)
- Market cap
- £23.10M
- Day range
- £0.06 – £0.06
- P/E
- -0.33
- Dividend yield
- None
- Volume
- 1.33M
- 1 month
- +51.81%
- 6 months
- +168.09%
- YTD
- +6.78%
- 1 year
- -33.68%
- 5 years
- -99.13%
Renalytix statements, FY2021–FY2025
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $3.0M | $2.3M | $3.4M | $3.0M | $1.5M |
| Gross profit | $1.2M | $156.0K | $701.0K | $874.0K | $633.0K |
| Operating income | −$17.2M | −$29.6M | −$42.4M | −$53.2M | −$31.9M |
| Net income | −$20.4M | −$33.5M | −$45.6M | −$45.3M | −$34.7M |
| Earnings per share | −$0.21 | −$0.31 | −$0.55 | −$0.63 | −$0.49 |
| EBITDA | −$21.3M | −$28.5M | −$41.7M | −$52.7M | −$32.7M |
| Total assets | $6.1M | $8.0M | $30.6M | $50.1M | $102.6M |
| Total debt | $8.3M | $8.5M | $12.2M | $12.3M | $352.0K |
| Cash and short-term investments | $3.7M | $5.4M | $24.7M | $41.3M | $74.5M |
| Shareholders' equity | −$7.0M | −$7.9M | $7.0M | $30.6M | $71.5M |
| Operating cash flow | −$17.9M | −$30.1M | −$34.1M | −$45.7M | −$24.6M |
| Free cash flow | −$17.9M | −$30.1M | −$32.7M | −$46.4M | −$26.3M |
| Capital expenditure | −$6.3 | −$4.0K | $0.0 | −$694.0K | −$1.6M |
Fiscal years as reported, the latest ending 30 Jun 2025. Figures in USD; a dash means the provider reported nothing for that line.
Peer comparison
| Company | Ticker | Price | Market cap |
|---|---|---|---|
| Poolbeg Pharma | POLB.L | £0.08 | £57.26M |
| Sareum | SAR.L | £0.32 | £44.19M |
| Novacyt | NCYT.L | £0.42 | £30.55M |
| Arecor Therapeutics | AREC.L | £0.72 | £27.35M |
| Inspiration Healthcare | IHC.L | £0.19 | £17.04M |
| Cambridge Cognition | COG.L | £0.29 | £15.65M |
| SkinBioTherapeutics | SBTX.L | £0.06 | £15.05M |
| Aptamer | APTA.L | £0.00 | £10.41M |
Peers as grouped by the data provider. This is not an investment recommendation.
Analyst price targets
- Low
- —
- High
- —
- Median
- —
- Consensus
- —
Ratings: 4 buy · 0 hold · 0 sell. Consensus: Buy.
Published sell-side 12-month targets in GBP, aggregated by the data provider. They are not Paasa's view and not a forecast.
How to invest in Renalytix from India
Step 1
Open your Paasa account
KYC takes a few minutes: PAN, Aadhaar and address proof. Your brokerage account is opened in your own name with Interactive Brokers.
Step 2
Add funds from your Indian bank account
Remit up to $250,000 a year under the RBI's Liberalised Remittance Scheme. Your bank converts the rupees to US dollars at its rate on the day you remit, and Interactive Brokers converts the dollars to GBP when you buy.
Step 3
Search RENX and buy
Find Renalytix by name or by its ticker, RENX, and place your order.
Why invest in Renalytix from India
What Renalytix does
Renalytix Plc specializes in developing cutting-edge in vitro diagnostic solutions for kidney diseases, leveraging the power of artificial intelligence. Their primary offering, KidneyIntelX, is an advanced diagnostic platform. Renalytix operates in the Medical - Healthcare Information Services industry within the Healthcare sector.
Paasa handles the paperwork
Investing abroad brings paperwork with it: remittance filings, capital gains reporting, foreign asset disclosure. Paasa prepares all of it for you. Your India-ready tax reports arrive at year end, ready to file.
Here's what inheritance rules in the UK mean for your Renalytix shares.
Shares in UK-incorporated companies are UK-situs assets and fall within UK Inheritance Tax, charged at 40% above the £325,000 threshold for non-residents.
Frequently asked questions
Can I buy Renalytix stock from India?
Yes. Indian residents and NRIs can buy Renalytix (RENX) shares directly through Paasa. Renalytix is listed on the London Stock Exchange, in the Medical - Healthcare Information Services industry. Your money leaves India under the RBI's Liberalised Remittance Scheme and the shares are held in your own name at Interactive Brokers.
How are Renalytix dividends taxed for Indian investors?
Renalytix does not currently pay a dividend, so there is nothing to withhold or declare today. If it starts paying one, the UK levies 0% withholding tax on company dividends paid to non-residents, and dividends are taxed at your slab rate in India.
What tax do I pay in India when I sell Renalytix shares?
Non-residents are exempt from UK capital gains tax on the disposal of listed shares. In India, gains on shares held for more than 24 months are long-term and taxed at 12.5%, and gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. Both are worked out in rupees at the GBP/INR rate on the day you bought and the day you sold, so the currency move is part of the gain. Paasa's capital-gains statement gives you the figures for your return.
What happens to my Renalytix shares if I pass away?
Shares in UK-incorporated companies are UK-situs assets and fall within UK Inheritance Tax, charged at 40% above the £325,000 threshold for non-residents. The rule looks at everything you hold there, not at Renalytix alone.
Is there stamp duty when I buy Renalytix shares?
The UK charges 0.5% Stamp Duty Reserve Tax when buying direct company shares electronically on the LSE; ETFs and UCITS funds do not attract it.